{"id":36191,"date":"2026-02-25T10:54:26","date_gmt":"2026-02-25T15:54:26","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=36191"},"modified":"2026-02-25T10:54:29","modified_gmt":"2026-02-25T15:54:29","slug":"beyond-the-drug-patent-cliff-how-procurement-can-drive-immediate-savings-with-generics-and-biosimilars","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/beyond-the-drug-patent-cliff-how-procurement-can-drive-immediate-savings-with-generics-and-biosimilars\/","title":{"rendered":"Beyond the Drug Patent Cliff: How Procurement Can Drive Immediate Savings with Generics and Biosimilars"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

The global biopharmaceutical industry is approaching a critical juncture as it faces a massive wave of patent expirations for some of the most successful therapeutic agents in medical history. This phenomenon, colloquially termed the patent cliff, represents a significant turning point for healthcare systems, pharmaceutical manufacturers, and procurement organizations. Between 2025 and 2030, the industry anticipates that nearly 200 drugs, including approximately 70 blockbuster medications with annual sales exceeding $1 billion each, will lose their market exclusivity.1<\/sup> The total revenue at risk during this window is estimated to exceed $300 billion, with some projections reaching as high as $400 billion by 2033 as foundational patents for top-selling therapies like Keytruda, Eliquis, and Opdivo lapse.1<\/sup><\/p>\n\n\n\n

For procurement professionals, this transition represents a unique opportunity to achieve immediate and sustainable cost savings. The entry of generic and biosimilar competitors typically leads to rapid price erosion and increased market competition. Historically, small-molecule generics have been known to capture up to 90% of a brand-name drug’s revenue within the first year of loss of exclusivity (LOE).2<\/sup> However, the current wave of expirations is increasingly dominated by biologics\u2014large, complex molecules derived from living organisms\u2014which present a different set of challenges and opportunities.3<\/sup> Unlike the sharp revenue “cliffs” seen with small molecules, biologics often experience a “slope,” with market share losses for originators ranging between 30% and 70% in the first year due to the growing but still maturing presence of biosimilars.3<\/sup><\/p>\n\n\n\n

Strategic procurement in this era must move beyond tactical purchasing to become a sophisticated orchestrator of value, risk, and innovation.6<\/sup> This necessitates a deep understanding of the regulatory pathways, the intricate legal frameworks of the Biologics Price Competition and Innovation Act (BPCIA), and the evolving dynamics of the Pharmacy Benefit Manager (PBM) market.7<\/sup> By leveraging advanced intelligence tools to track patent timelines and adopting a Total Cost of Ownership (TCO) approach, procurement teams can navigate the complexities of rebate walls and patent thickets to secure the next generation of affordable therapies.6<\/sup><\/p>\n\n\n\n

The Anatomy of the 2025-2030 Patent Cliff<\/strong><\/h2>\n\n\n\n

The pharmaceutical industry is entering a cyclical but historically significant period of revenue vulnerability. The upcoming patent cliff is distinguished by the sheer volume of multi-billion dollar assets facing competition simultaneously.12<\/sup> Large pharmaceutical firms, including Pfizer, Bristol Myers Squibb (BMS), Merck, and Novartis, are bracing for losses that could affect more than 30% of their collective 2024 revenues.13<\/sup> This revenue decline is immediate upon the loss of exclusivity, forcing firms to execute across-the-board Research and Development (R&D) cutbacks and layoffs, signaling constrained investment in novel drug discovery.1<\/sup><\/p>\n\n\n\n

Revenue Vulnerability and Strategic Responses<\/strong><\/h3>\n\n\n\n

The financial stakes are particularly high for companies whose revenue is highly concentrated in a single blockbuster. For instance, Merck\u2019s Keytruda, which generated over $29 billion in 2023, is set to lose core patent protection in 2028.12<\/sup> Similarly, the anticoagulant Eliquis, co-marketed by BMS and Pfizer, faces a cliff between 2026 and 2028, threatening over $18 billion in combined annual revenue.12<\/sup> To patch these impending holes, manufacturers are leaning on new therapeutic stars. AbbVie, for instance, has successfully introduced Skyrizi and Rinvoq to offset the sharp decline of Humira, which saw revenue fall from $21.2 billion in 2022 to just $9 billion in 2024 following its LOE.1<\/sup><\/p>\n\n\n\n

Strategic responses from major players often involve a blend of lifecycle extensions, evergreening, and aggressive Mergers and Acquisitions (M&A). Evergreening strategies include reformulating existing drugs or identifying new therapeutic uses to secure additional patents.1<\/sup> In terms of M&A, recent record-paced deals aim to fast-track the development of new treatments and diversify portfolios. Notable examples include Pfizer’s $43 billion investment in cancer therapies and Merck\u2019s $10 billion acquisition of Verona Pharma to leverage high-potential assets.1<\/sup><\/p>\n\n\n\n

The Blockbuster Hit List 2024-2030<\/strong><\/h3>\n\n\n\n

The following table outlines the critical assets approaching the end of their market exclusivity, highlighting the massive financial exposure of the primary innovators.<\/p>\n\n\n\n

Drug (Brand)<\/strong><\/td>Generic \/ Biosimilar Name<\/strong><\/td>Innovator Company<\/strong><\/td>Primary Indication<\/strong><\/td>Patent Expiry (U.S.)<\/strong><\/td>Sales (Recent Annual)<\/strong><\/td><\/tr>
Keytruda<\/td>Pembrolizumab<\/td>Merck<\/td>Oncology (PD-1)<\/td>2028<\/td>$29.0 Billion 13<\/sup><\/td><\/tr>
Eliquis<\/td>Apixaban<\/td>BMS \/ Pfizer<\/td>Anticoagulant<\/td>2026-2027<\/td>$18.0 Billion+ 12<\/sup><\/td><\/tr>
Humira<\/td>Adalimumab<\/td>AbbVie<\/td>Immunology<\/td>2023 (Active LOE)<\/td>$21.2 Billion (2022) 1<\/sup><\/td><\/tr>
Stelara<\/td>Ustekinumab<\/td>J&J<\/td>Immunology<\/td>2025<\/td>$10.0 Billion+ 16<\/sup><\/td><\/tr>
Ozempic<\/td>Semaglutide<\/td>Novo Nordisk<\/td>Diabetes \/ Obesity<\/td>2026 (Key Patent)<\/td>$20.0 Billion (Global) 18<\/sup><\/td><\/tr>
Eylea<\/td>Aflibercept<\/td>Regeneron<\/td>Ophthalmology<\/td>2024-2025<\/td>$9.0 Billion 12<\/sup><\/td><\/tr>
Entresto<\/td>Sacubitril\/Valsartan<\/td>Novartis<\/td>Heart Failure<\/td>2025<\/td>$7.8 Billion 13<\/sup><\/td><\/tr>
Farxiga<\/td>Dapagliflozin<\/td>AstraZeneca<\/td>Diabetes<\/td>2025<\/td>$7.7 Billion 13<\/sup><\/td><\/tr>
Soliris<\/td>Eculizumab<\/td>AstraZeneca<\/td>Rare Disease<\/td>2025<\/td>$2.6 Billion 13<\/sup><\/td><\/tr>
Ibrance<\/td>Palbociclib<\/td>Pfizer<\/td>Breast Cancer<\/td>2027<\/td>$5.0 Billion+ 14<\/sup><\/td><\/tr>
Xtandi<\/td>Enzalutamide<\/td>Pfizer<\/td>Prostate Cancer<\/td>2027<\/td>$1.0 Billion+ 14<\/sup><\/td><\/tr>
Januvia<\/td>Sitagliptin<\/td>Merck<\/td>Diabetes<\/td>2026-2027<\/td>$2.2 Billion 18<\/sup><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Procurement leaders must act now to safeguard innovation and market access, mobilizing early to preserve revenue streams and R&D momentum.1<\/sup> For traditional small-molecule drugs, the arrival of generics marks a vanishes moat, where competitors flood the market. For more complex biological drugs, the launch of biosimilars reshapes the competitive landscape fundamentally, albeit at a more gradual pace than their small-molecule counterparts.12<\/sup><\/p>\n\n\n\n

The Biologic Paradigm and the Slope of Exclusivity<\/strong><\/h2>\n\n\n\n

A critical driver of the current market disruption is the transition from small-molecule drugs to biologics. Biologics now account for a significant portion of pharmaceutical spending, particularly in specialty categories like oncology and inflammatory conditions.19<\/sup> While small-molecule generics are chemically identical to their reference products, biosimilars are highly similar but not identical, due to the inherent variability of production in living cells.4<\/sup><\/p>\n\n\n\n

Technical and Financial Hurdles in Biosimilar Development<\/strong><\/h3>\n\n\n\n

The regulatory barrier for biosimilars is substantially higher than for generics. Obtaining licensure requires demonstrating that the product is highly similar to the already-licensed biologic with no clinically meaningful differences in safety, purity, and potency.4<\/sup> Developing a biosimilar requires an investment of approximately $100 million to $250 million over seven to eight years, compared to the significantly lower cost and time required for generic small-molecule drugs.22<\/sup><\/p>\n\n\n\n

The intricacies of investment decisions for biosimilar development are compounded by rigorous technical requirements. Clinical development represents the largest share of total development costs, estimated at 57%.22<\/sup> These figures influence market dynamics; while a small-molecule drug may attract dozens of generic competitors, a biologic may only face a handful of biosimilar challengers, leading to more moderate price decreases and a slower erosion of the originator\u2019s market share.3<\/sup> Successful projects typically require minimum peak sales of $250 million to $300 million to achieve a positive Net Present Value (NPV).22<\/sup><\/p>\n\n\n\n

Cost Distribution in Biosimilar Development Programs<\/strong><\/h3>\n\n\n\n

The following data provides a breakdown of the capital required to bring a biosimilar to market, underscoring why competition is limited to well-capitalized firms.<\/p>\n\n\n\n

Development Phase<\/strong><\/td>Cost Range ($Millions)<\/strong><\/td>Percentage of Total<\/strong><\/td><\/tr>
Process Development<\/td>$25 – $35<\/td>18%<\/td><\/tr>
Clinical Development<\/td>$80 – $120<\/td>57%<\/td><\/tr>
Manufacturing Setup<\/td>$30 – $45<\/td>20%<\/td><\/tr>
Regulatory Filing<\/td>$5 – $8<\/td>5%<\/td><\/tr>
Total Investment<\/strong><\/td>$140 – $208<\/strong><\/td>100%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Research indicates that early market entry provides a substantial NPV advantage, while manufacturing optimization significantly impacts project value.22<\/sup> Despite these high costs, biosimilars typically launch at prices 30% to 40% lower than the reference products, providing a critical lever for expanding treatment options and improving outcomes for communities.20<\/sup><\/p>\n\n\n\n

Strategic Procurement Frameworks for Immediate Savings<\/strong><\/h2>\n\n\n\n

In the face of the patent cliff, procurement is no longer a back-office function tasked solely with securing the lowest unit price. Modern procurement operates as a strategic orchestrator that balances cost, quality, and supply chain resilience.6<\/sup> To drive immediate savings, procurement teams must adopt advanced frameworks that look beyond simple acquisition costs.<\/p>\n\n\n\n

Total Cost of Ownership (TCO) vs. Acquisition Cost<\/strong><\/h3>\n\n\n\n

The traditional focus on the lowest invoice price has often led to a race to the bottom that ignores the hidden costs of supply chain fragility and quality failures.10<\/sup> A robust TCO model in pharmaceutical procurement accounts for the entire lifecycle of the drug, incorporating risks that can far outweigh initial savings.6<\/sup> The true cost of a drug is not its purchase price but the total cost of ensuring its uninterrupted availability and quality.10<\/sup><\/p>\n\n\n\n

A modern TCO framework must evolve to integrate associated risks and environmental impacts, such as carbon emissions ($CO_{2}e$). The integrated formula can be represented as:<\/p>\n\n\n\n

$$\\text{TCO} = \\text{Acquisition Cost} + \\text{Risk Factor} + \\text{CO}_{2}\\text{e Impact}$$<\/p>\n\n\n\n

This redfined formula Redefines how pharmaceutical supply chains operate by focusing on reducing expenses, mitigating risks, and lowering environmental impact together.24<\/sup> It empowers stakeholders to weigh critical factors holistically based on their contributions to cost efficiency and responsibility.<\/p>\n\n\n\n

Comparative TCO Metrics: Brand-Name vs. Generic Suppliers<\/strong><\/h3>\n\n\n\n

The power of the TCO model is revealed when hidden costs\u2014such as the labor costs of shortage management\u2014are quantified. When a low-cost supplier fails to deliver, the ripple effects are expensive and can include clinical disruptions and the need for emergency alternatives.10<\/sup><\/p>\n\n\n\n

Cost Category<\/strong><\/td>Option 1: Brand-Name Drug<\/strong><\/td>Option 2: Generic Supplier A (Lowest Price)<\/strong><\/td><\/tr>
Initial Acquisition Cost<\/td>High<\/td>Low<\/td><\/tr>
Cost of Emergency Alternatives<\/td>$5,000<\/td>$500,000<\/td><\/tr>
Inventory Carrying Costs<\/td>$200,000<\/td>$80,000<\/td><\/tr>
Administrative Overhead<\/td>$25,000<\/td>$50,000<\/td><\/tr>
Estimated Cost of Quality Failures<\/td>$1,000<\/td>$150,000<\/td><\/tr>
Projected Total Cost<\/strong><\/td>Moderate but Stable<\/strong><\/td>High and Volatile<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Procurement teams must conduct deep-tier audits of their supply base to identify exposure to geographic concentration.6<\/sup> A robust generic supplier scorecard should heavily weight factors like manufacturing redundancy, FDA inspection history (such as Form 483s and warning letters), and historical failure-to-supply track records.10<\/sup><\/p>\n\n\n\n

Value-Based Procurement and MEAT Frameworks<\/strong><\/h3>\n\n\n\n

Increasingly, healthcare systems are adopting Value-Based Procurement (VBP) models, specifically the Most Economically Advantageous Tender (MEAT) framework.25<\/sup> This approach evaluates tenders based on a weighted matrix of criteria rather than price alone. In biosimilar procurement, the MEAT framework often includes a systematic approach incorporating multi-criteria decision analysis (MCDA) to offer a transparent framework for incorporating diverse considerations essential for sustainable markets.25<\/sup><\/p>\n\n\n\n

Typical scoring matrices in these environments include several qualitative criteria:<\/p>\n\n\n\n